This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Search results
From Proteopedia
You searched for Pharmacokinetic
There is no page with the exact title "Pharmacokinetic". The search results for "Pharmacokinetic" are displayed below. You can create a page titled Pharmacokinetic (by clicking on the red link).
For more information about searching Proteopedia, see Help.
To exclude pages titled with 4-character PDB codes, use the checkbox "only Human created pages" at the bottom of this page.
Showing below up to 20 results starting with #1.
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
Article title matches
- Category:Pharmacokinetic (46 bytes)
1: List of pages with the keyword Pharmacokinetic - Category:Pharmacokinetic property (55 bytes)
1: List of pages with the keyword Pharmacokinetic property - Category:Pharmacokinetic sensor (53 bytes)
1: List of pages with the keyword Pharmacokinetic sensor
Page text matches
- 2j94 (5,654 bytes)
26: ...rved within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivit... - 2j95 (5,600 bytes)
26: ...rved within this series of potent fXa inhibitors. Pharmacokinetic profiles in rat and dog, together with selectivit... - 1h1b (6,554 bytes)
26: ...ibitors, with a prolonged pharmacodynamic action. Pharmacokinetically, these compounds are comparable with 1 while ... - 2jc1 (9,028 bytes)
24: ...ubmicromolar potency in the HCV replicon and good pharmacokinetic properties. - 2jc0 (9,030 bytes)
24: ...ubmicromolar potency in the HCV replicon and good pharmacokinetic properties. - 2uzw (7,305 bytes)
24: ...improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors... - 2uzt (7,322 bytes)
24: ...improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors... - 2uzu (7,340 bytes)
24: ...improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors... - 2uzv (5,295 bytes)
24: ...improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors... - 2j14 (4,553 bytes)
24: ...nvestigated and optimized for a favorable in vivo pharmacokinetic profile. Isoxazole LCI765 (17d) was found to be a... - 2j50 (5,903 bytes)
24: ...cancer cell lines, favorable chemico-physical and pharmacokinetic properties, and high efficacy in in vivo tumor mo... - 1w5w (11,987 bytes)
24: ...e development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants. - 1w5y (11,987 bytes)
24: ...e development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants. - 1w5x (11,987 bytes)
24: ...e development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants. - 1w5v (11,924 bytes)
24: ...e development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants. - 1uom (6,986 bytes)
24: ...fect of N-phenyl substituents on the activity and pharmacokinetic properties of tetrahydroisoquinoline analogues wa... - 2bm2 (5,402 bytes)
24: ...change of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioa... - 2bhj (4,257 bytes)
24: ...wo compounds (16 and 30) demonstrate a reasonable pharmacokinetic profile in rodents. The synthesis, SAR, and biolo... - 4j3j (5,239 bytes)
14: ...e performed on this series, revealing undesirable pharmacokinetic profiles for the triazole compounds. To overcome ... - 2j4z (5,883 bytes)
24: ...cancer cell lines, favorable chemico-physical and pharmacokinetic properties, and high efficacy in in vivo tumor mo...
View (previous 20) (next 20) (20 | 50 | 100 | 250 | 500)
You may also try
